E2F3

Across TCGA pan-cancer cohorts, E2F3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated E2F3 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher E2F3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated E2F3 expression acts as an unfavorable survival marker.

THCA, LUSC, and LIHC are the cancer types where E2F3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	OS	Median	All	0.098	0.941	<.001	42	view →
LUSC	DFS	Median	All	0.079	0.792	<.001	30	view →
LIHC	DFS	Median	II,III,IV	0.077	0.463	.002	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

E2F3–THCA (OS)

Open the THCA breakdown →